Skip to main content

Table 4 Cost-effectiveness results of base case

From: Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective

Treatment regimen

Total costs

QALYs

Incremental cost per QALY gained

DEX (SOC)

R 8 312

1.14

 

BORT

R 234 995

1.49

R 654 649

LEN/DEX

R 1 135 323

2.22

R 1 225 542

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us